Survival Outcomes in Sinonasal Poorly Differentiated Squamous Cell Carcinoma

Ackall, Feras Y.; Issa, Khalil; Teitelbaum, Jordan I; Jang, David W.; Jung, Sin‐Ho; Hachem, Ralph Abi

doi:10.1055/s-0040-1702309

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IC + surgery + adjuvant therapy group had the lowest incidence of DS, followed by the surgery + adjuvant therapy group. Based on the 1-, 2-, and 3-year OS of each group, we observed that the IC + surgery + adjuvant therapy group had a significant advantage in OS compared with the other two treatments, which was also consistent with our previous hypothesis and the previous literature (13).…”

Section: Discussionsupporting

confidence: 91%

Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

et al. 2022

View full text Add to dashboard Cite

Background: Although poorly differentiated is rare in head and neck squamous cell carcinoma (HNSCC), its prognosis are worse with high rate of local recurrence and distant metastasis (DS). Therefore, this study hopes to carry out prospective clinical research on different treatment options for poorly differentiated patients and explore the treatment scheme more suitable for these patients.Methods: This study is a prospective cohort study. We selected patients with poorly differentiated carcinoma in larynx or hypopharynx (stage I-IV, T1-4a, N0-2, M0). The intervention treatment methods for stage I-II patients are as follows: surgery, induction chemotherapy (IC) + surgery, surgery + adjuvant therapy; The intervention treatment methods for stage III-IV patients are as follows: surgery, IC + surgery + adjuvant therapy, surgery + adjuvant therapy. The patients were followed up for at least 1 year, and the disease progression and survival were counted. Results:From September 2016 to October 2020, 62 patients were included (29 patients in stage I/II and 33 patients in stage III/IV). We found that there was no significant difference in survival between treatment groups in stage I/II patients [overall survival (OS): P=0.447; progression free survival (PFS): P=0.504], but the surgery + adjuvant treatment group had a significant advantage in 3-year OS (100%). In stage III/IV patients, there were significant differences in DS, OS and PFS between different treatment groups (DS: P=0.013; OS: P=0.021; PFS: P=0.020). Among them, the survival rate of IC + surgery + adjuvant treatment group was the best, with 3-year OS of 78%.Conclusions: Our study found that postoperative radiotherapy may improve the OS rate of patients with early (stage I/II) poorly differentiated HNSCC; For advanced patients (stage III/IV), surgery combined with IC and postoperative adjuvant radiotherapy may better control DS and improve the survival rate. However, our study draws the above conclusions based on small sample data, and we will continue to summarize and expand the sample size for verification.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

et al. 2022

View full text Add to dashboard Cite

show abstract

“…11,14,15,19 There are multiple studies demonstrating the survival benefit of PORT. 20,21 Given the robust data in favor of radiation therapy, it is likely that the relatively small sample size of patients refusing PORT (n ¼ 73) precluded a significant difference in survival in our study. In addition, the patients who refused PORT had lower T stage tumors, which highlights some baseline differences in the cohorts.…”

Section: Discussionmentioning

confidence: 98%

Determinants of Patient Refusal of Postoperative Radiation Therapy in Sinonasal Squamous Cell Carcinoma

Kshirsagar

Eide

Prasad

et al. 2022

J Neurol Surg B Skull Base

View full text Add to dashboard Cite

Objectives Although adjuvant radiotherapy may be indicated in patients with sinonasal squamous cell carcinoma (SNSCC) following primary surgery, some patients choose to forgo recommended post-operative radiation (PORT). This study aimed to elucidate factors associated with patient refusal of recommended PORT in SNSCC and examine overall survival. Methods Retrospective analysis of patients with SNSCC treated with primary surgery from the National Cancer Database diagnosed between 2004 and 2016. A multivariable logistic regression model was created to determine the association between clinical or demographic covariates and likelihood of PORT refusal. Unadjusted Kaplan-Meier estimates, log-rank tests, and a multivariable Cox proportional hazard model were used to assess overall survival. Results 2231 patients were included in the final analysis, of which 1456 (65.3%) were male and 73 (3.3%) refused recommended PORT. Patients older than 74 years old were more likely to refuse PORT than those younger than 54 (OR 3.43, 95% CI: 1.84-6.62). Median survival among the entire cohort, those that received recommended PORT, and those that refused PORT was 83.0 months (95% CI: 74.6-97.1), 83.0 months (95% CI: 74.9-98.2), and 63.6 months (95% CI: 37.3-101.4). Refusal of PORT was not associated with overall survival (HR 0.99, 95% CI: 0.69-1.42). Conclusions PORT refusal in patients with SNSCC is rare and was found to be associated with several patient factors. The decision to forgo PORT is not independently associated with overall survival in this cohort. Further study is required to determine the clinical implications of these findings as the treatment decisions are complex.

show abstract

“…SNSCCs are the most common sinonasal malignancy, making up approximately 3% of head and neck cancers 10 . Within sinonasal malignancies, SNSCC is the most common, making up 61% of cases 11 .…”

Section: Sinonasal Squamous Cell Carcinomamentioning

confidence: 99%

“…SNSCCs are the most common sinonasal malignancy, making up approximately 3% of head and neck cancers. 10 Within sinonasal malignancies, SNSCC is the most common, making up 61% of cases. 11 A recent study examined 4994 cases of SNSCC between 1973 and 2009, as documented by the National Cancer Institute's Surveillance Epidemiology and End Results (SEER) program, which revealed that the overall incidence rate was 0.36 cases per 100,000 population per year.…”

Section: Sinonasal Squamous Cell Carcinoma Incidence and Patient Demo...mentioning

confidence: 99%

The contemporary management of cancers of the sinonasal tract in adults

Thawani

Kim

Arastu

et al. 2022

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Sinonasal malignancies make up <5% of all head and neck neoplasms, with an incidence of 0.5–1.0 per 100,000. The outcome of these rare malignancies has been poor, whereas significant progress has been made in the management of other cancers. The objective of the current review was to describe the incidence, causes, presentation, diagnosis, treatment, and recent developments of malignancies of the sinonasal tract. The diagnoses covered in this review included sinonasal undifferentiated carcinoma, sinonasal adenocarcinoma, sinonasal squamous cell carcinoma, and esthesioneuroblastoma, which are exclusive to the sinonasal tract. In addition, the authors covered malignances that are likely to be encountered in the sinonasal tract—primary mucosal melanoma, NUT (nuclear protein of the testis) carcinoma, and extranodal natural killer cell/T‐cell lymphoma. For the purpose of keeping this review as concise and focused as possible, sarcomas and malignancies that can be classified as salivary gland neoplasms were excluded.

show abstract

Survival Outcomes in Sinonasal Poorly Differentiated Squamous Cell Carcinoma

Cited by 4 publications

References 0 publications

Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

Clinical study of poorly differentiated head and neck squamous cell carcinoma: a prospective cohort study in China

Determinants of Patient Refusal of Postoperative Radiation Therapy in Sinonasal Squamous Cell Carcinoma

The contemporary management of cancers of the sinonasal tract in adults

Contact Info

Product

Resources

About